PHVS,ADCT Stock Price and Quote

Peers: MIRM PTCT BMRN KYMR INCY RYTM KRYS NUVL ALNY AUPH

| Held by: IBB IEFA SCZ SBIO EWN ONEQ GWX BBC IBBQ IEUS

Index	-	P/E	-	EPS (ttm)	-3.18	Insider Own	57.63%	Shs Outstand	65.42M	Perf Week	-1.24%
Market Cap	2.09B	Forward P/E	-	EPS next Y	-2.73	Insider Trans	-0.59%	Shs Float	29.36M	Perf Month	1.11%
Enterprise Value	1.81B	PEG	-	EPS next Q	-0.77	Inst Own	40.34%	Short Float	2.05%	Perf Quarter	6.23%
Income	-195.21M	P/S	-	EPS this Y	11.27%	Inst Trans	-0.48%	Short Ratio	2.22	Perf Half Y	18.51%
Sales	0.00M	P/B	7.25	EPS next Y	10.97%	ROA	-68.82%	Short Interest	0.60M	Perf YTD	8.68%
Book/sh	4.16	P/C	7.34	EPS next 5Y	30.81%	ROE	-75.71%	52W High	33.33 -9.51%	Perf Year	80.38%
Cash/sh	4.11	P/FCF	-	EPS past 3/5Y	-11.96% -21.68%	ROIC	-71.53%	52W Low	15.51 94.46%	Perf 3Y	249.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.96% 5.08%	Perf 5Y	47.12%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.22%	Oper. Margin	-	ATR (14)	1.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.24	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.86	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	11.24	EPS Q/Q	21.54%	SMA20	0.30%	Beta	-2.35	Target Price	46.42
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	4.62%	Rel Volume	1.53	Prev Close	29.86
Employees	129	LT Debt/Eq	0.00	Earnings	May 12 AMC	SMA200	16.71%	Avg Volume	270.42K	Price	30.16
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.03% -	Trades		Volume	413,891	Change	1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Initiated	Wolfe Research	Outperform	$42
Mar-09-26	Initiated	RBC Capital Mkts	Outperform	$52
Oct-15-25	Initiated	H.C. Wainwright	Buy	$60
Oct-09-25	Upgrade	BofA Securities	Underperform → Neutral	$27
Jun-11-25	Initiated	Guggenheim	Buy	$32
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$28
Sep-25-23	Initiated	Wedbush	Outperform	$27
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$10 → $34
Oct-05-22	Initiated	Bryan Garnier	Buy	$16
Sep-13-22	Resumed	JMP Securities	Mkt Outperform	$34 → $18
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$40 → $10
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform	$26 → $13
May-25-22	Initiated	JMP Securities	Mkt Outperform	$34
Mar-02-21	Initiated	SVB Leerink	Outperform	$50
Mar-02-21	Initiated	Oppenheimer	Outperform	$48
Mar-02-21	Initiated	Morgan Stanley	Overweight	$51
Mar-02-21	Initiated	BofA Securities	Neutral	$41

Show Previous Ratings

May-29-26 06:50AM	Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 (GlobeNewswire)
May-12-26 04:05PM	Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +5.41%
May-11-26 04:15PM	Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-08-26 06:00AM	Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares (GlobeNewswire)
Apr-20-26 06:50AM	Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference (GlobeNewswire)
09:40AM	Loading…
Apr-09-26 09:40AM	Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls (The Fly)
Apr-02-26 06:50AM	Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-01-26 08:00PM	Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect? (Quartz)
Mar-20-26 06:50AM	Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology (GlobeNewswire)
Mar-11-26 06:50AM	Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology (GlobeNewswire) +5.95%
Mar-02-26 06:50AM	Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 (GlobeNewswire)
Feb-10-26 06:50AM	Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting (GlobeNewswire)
Jan-12-26 06:50AM	Pharvaris Outlines 2026 Strategic Priorities (GlobeNewswire)
Dec-21-25 09:57AM	What Does Wall Street Think About Pharvaris N.V. (PHVS)? (Insider Monkey)
Dec-04-25 01:09PM	Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals (Zacks) -5.70%
04:15PM	Loading…
Dec-03-25 04:15PM	Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment (Investor's Business Daily) +21.75%
06:50AM	Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks (GlobeNewswire)
Nov-12-25 06:50AM	Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.01%
Nov-10-25 06:50AM	Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-23-25 06:50AM	Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting (GlobeNewswire)
Aug-12-25 04:05PM	Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-24-25 04:05PM	Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-22-25 09:22PM	Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) -9.86%
04:05PM	Pharvaris Announces Proposed Public Offering of Ordinary Shares (GlobeNewswire)
Jul-10-25 06:50AM	Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 (GlobeNewswire) +7.19%
Jun-27-25 06:50AM	Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit (GlobeNewswire) -5.03%
Jun-16-25 06:50AM	Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress (GlobeNewswire)
Jun-10-25 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)
Jun-02-25 06:50AM	Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema (GlobeNewswire)
May-19-25 06:50AM	Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses (GlobeNewswire)
04:05PM	Loading…
May-13-25 04:05PM	Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-12-25 06:50AM	Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4 (GlobeNewswire)
Apr-07-25 06:58AM	Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.49%
Apr-02-25 06:30AM	EC grants orphan designation for Pharvaris' deucrictibant drug (Pharmaceutical Business Review)
Apr-01-25 06:50AM	Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission (GlobeNewswire) -5.54%
Mar-03-25 06:50AM	Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress (GlobeNewswire)
06:48AM	Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire)
Jan-31-25 02:01PM	Why Pharvaris (PHVS) Is Advancing Today (Insider Monkey)
Jan-23-25 02:07AM	Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? (Insider Monkey)
Jan-13-25 06:50AM	Pharvaris Outlines 2025 Strategic Priorities (GlobeNewswire) -7.81%
Dec-06-24 06:47AM	Pharvaris price target lowered to $46 from $50 at JMP Securities (TipRanks)
Nov-13-24 04:10PM	Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Nov-12-24 06:50AM	Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference (GlobeNewswire) -6.64%
Oct-30-24 06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-24-24 08:00AM	Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting (GlobeNewswire)
Oct-16-24 06:50AM	Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings (GlobeNewswire)
Oct-15-24 06:50AM	Pharvaris to Host Virtual Investor Event on October 23, 2024 (GlobeNewswire)
Oct-03-24 06:50AM	Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop (GlobeNewswire)
Sep-05-24 06:50AM	Pharvaris Provides Business Update and Expands Development Program for Deucrictibant (GlobeNewswire) +10.34%
06:49AM	Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 (GlobeNewswire)
06:48AM	Pharvaris Presents Data at the Bradykinin Symposium 2024 (GlobeNewswire)
Aug-28-24 06:50AM	Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium (GlobeNewswire)
Aug-14-24 06:50AM	Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.55%
Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
Jun-11-24 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)
Jun-04-24 06:50AM	Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses (GlobeNewswire) -5.31%
May-13-24 06:50AM	Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses (GlobeNewswire)
May-08-24 11:55PM	PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 (InvestorPlace) -7.82%
04:10PM	Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-10-24 09:52PM	PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
04:08PM	Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer (GlobeNewswire)
Apr-04-24 06:50AM	Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference (GlobeNewswire)
Mar-18-24 06:50AM	Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses (GlobeNewswire) +6.34%
Mar-06-24 06:50AM	Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses (GlobeNewswire) +5.86%
Mar-05-24 06:50AM	Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 (GlobeNewswire)
Feb-22-24 06:50AM	Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting (GlobeNewswire)
Feb-16-24 06:50AM	Pharvaris Announces Extraordinary Meeting of Shareholders (GlobeNewswire)
Jan-26-24 06:50AM	Pharvaris to Present at the WSAAI Annual Meeting 2024 (GlobeNewswire)
Jan-23-24 09:34AM	Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program (Zacks)
Jan-22-24 04:07PM	Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision (Investor's Business Daily) +6.27%
07:34AM	FDA lifts remaining hold on Pharvaris' HAE drug, clearing path to phase 3 (FierceBiotech.com)
06:50AM	Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks (GlobeNewswire)
Jan-05-24 06:50AM	Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities (GlobeNewswire)
Dec-08-23 06:00PM	Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA LEN UCARE Conference 2023 (GlobeNewswire)
Dec-07-23 03:17PM	Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal (Zacks)
Dec-06-23 10:16AM	Why Is Pharvaris (PHVS) Stock Up 36% Today? (InvestorPlace) +18.14%
09:33AM	Pharvaris' oral hereditary angioedema med slashes attacks in turnaround post-FDA hold (FierceBiotech.com)
07:02AM	Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants (GlobeNewswire)
06:56AM	Pharvaris shares spike as drug appears to prevent symptoms of rare disorder (BioPharma Dive)
06:50AM	Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks (GlobeNewswire)
Nov-30-23 06:50AM	Pharvaris to Present at the GA LEN UCARE Conference 2023 (GlobeNewswire)
Nov-15-23 06:50AM	Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer (GlobeNewswire) -11.49%
Nov-09-23 11:00AM	Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting (GlobeNewswire)
Nov-02-23 06:50AM	Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 06:50AM	Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting (GlobeNewswire)
Oct-13-23 06:50AM	Pharvaris To Present at the APAAACI 2023 International Conference (GlobeNewswire)
Oct-04-23 07:34AM	Pharvaris To Present at the CIIC Fall 2023 Conference (GlobeNewswire)
Sep-19-23 06:50AM	Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) +16.68%
Sep-06-23 06:51AM	Pharvaris To Present at the 18th German Allergy Congress (GlobeNewswire)
06:50AM	Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-31-23 08:09PM	Expect at Least 60% Upside, Says Morgan Stanley About These 2 Buy-Rated Stocks (TipRanks)
Aug-23-23 06:50AM	Pharvaris To Present at the 2023 HAEi Regional Conference EMEA (GlobeNewswire)
Aug-15-23 09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly) +8.58%
Aug-07-23 06:50AM	Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -6.91%
Jul-21-23 10:20AM	Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit (GlobeNewswire)
Jul-03-23 08:16AM	Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 50% ownership, institutions own 18% (Simply Wall St.)
Jun-27-23 12:11PM	Why Shares of Pharvaris N.V. Are Up Tuesday (Motley Fool) +7.96%
Jun-26-23 02:27PM	FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE (Benzinga) +27.76%

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

M.B.A.Mr. Berndt Axel Edvard Modig CPA

CFOMr. David W. Nassif J.D.

R.A.Ms. Anna Nijdam M.Sc.

Chief Technology Operations OfficerDr. Stefan Abele Ph.D.

Chief Human Resources OfficerMs. Annick Deschoolmeester

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Monges Viviane	Director	May 21 '26	Sale	30.29	9,667	292,853	5,500	May 26 05:53 PM
Nijdam Anna	Principal Accounting Officer	May 22 '26	Option Exercise	20.00	5,501	110,020	54,446	May 26 05:45 PM
Nijdam Anna	Principal Accounting Officer	May 21 '26	Option Exercise	20.00	1,829	36,580	50,774	May 26 05:45 PM
Nijdam Anna	Principal Accounting Officer	May 22 '26	Sale	30.74	5,501	169,084	48,945	May 26 05:45 PM
Nijdam Anna	Principal Accounting Officer	May 21 '26	Sale	30.60	1,829	55,971	48,945	May 26 05:45 PM
Nassif David W.	CFO / CLO	May 21 '26	Sale	30.31	10,000	303,076	120,300	May 26 05:42 PM
ANNA NIJDAM	Officer	May 22 '26	Proposed Sale	30.74	5,501	169,084		May 22 05:03 PM
Bjork Elisabeth	Director	May 20 '26	Option Exercise	8.05	10,000	80,500	25,167	May 22 02:54 PM
Bjork Elisabeth	Director	May 20 '26	Sale	29.32	10,000	293,166	15,167	May 22 02:54 PM
ANNA NIJDAM	Officer	May 21 '26	Proposed Sale	30.60	1,829	55,971		May 21 05:35 PM
VIVIANE V. MONGES	Director	May 21 '26	Proposed Sale	30.29	9,667	292,853		May 21 05:31 PM
DAVID NASSIF	Officer	May 21 '26	Proposed Sale	30.31	10,000	303,076		May 21 05:27 PM
Modig Berndt	Chief Executive Officer	May 18 '26	Sale	29.22	2,292	66,977	137,500	May 20 05:33 PM
ELISABETH BJORK	Director	May 20 '26	Proposed Sale	29.32	10,000	293,166		May 20 05:23 PM
Glassman Robert	Director	May 15 '26	Option Exercise	22.31	5,333	118,979	20,500	May 19 06:48 PM
Glassman Robert	Director	May 15 '26	Sale	29.82	10,000	298,245	10,500	May 19 06:48 PM
Abele Stefan Andreas	Chief Technical Ops Officer	May 15 '26	Sale	29.82	8,748	260,864	35,194	May 19 06:44 PM
Souverijns Wim	Chief Commercial Officer	May 15 '26	Sale	29.92	10,000	299,163	45,111	May 19 06:42 PM
STEFAN ABELE	Officer	May 15 '26	Proposed Sale	29.82	8,748	260,864		May 15 05:50 PM
WIM SOUVERIJNS	Officer	May 15 '26	Proposed Sale	29.92	10,000	299,163		May 15 05:44 PM
Berndt B.A,E. Modig	Director	May 15 '26	Proposed Sale	30.70	2,292	70,364		May 15 04:31 PM
ROBERT GLASSMAN	Director	May 15 '26	Proposed Sale	29.82	8,804	262,567		May 15 04:14 PM
Lu Peng	Chief Medical Officer	May 01 '26	Option Exercise	2.59	14,166	36,690	80,249	May 05 03:51 PM
Lu Peng	Chief Medical Officer	May 01 '26	Sale	30.17	14,166	427,419	66,083	May 05 03:51 PM
Schikan Johannes Gerardus Chri	Director	Apr 30 '26	Sale	30.32	29,070	881,380	355,167	May 01 07:32 PM
Schikan Johannes Gerardus Chri	Director	Apr 29 '26	Sale	30.07	3,830	115,165	384,237	May 01 07:32 PM
Lesage Anne	Chief Early Development	Apr 30 '26	Option Exercise	7.12	21,700	154,483	74,450	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 29 '26	Option Exercise	2.59	3,700	9,583	60,150	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 30 '26	Sale	30.26	21,700	656,551	56,450	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 30 '26	Sale	30.26	19,200	580,909	133,969	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 29 '26	Sale	30.08	3,700	111,280	56,450	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 29 '26	Sale	30.06	3,700	111,229	153,169	May 01 07:30 PM
Lu Peng	Chief Medical Officer	Apr 30 '26	Option Exercise	2.59	15,000	38,850	81,083	May 01 07:09 PM
Lu Peng	Chief Medical Officer	Apr 29 '26	Option Exercise	2.59	3,733	9,668	69,816	May 01 07:09 PM
Lu Peng	Chief Medical Officer	Apr 30 '26	Sale	30.24	15,000	453,627	66,083	May 01 07:09 PM
Lu Peng	Chief Medical Officer	Apr 29 '26	Sale	30.06	3,733	112,232	62,350	May 01 07:09 PM
Schikan Johannes Gerardus Chri	Director	Apr 22 '26	Sale	30.05	7,000	210,379	388,167	Apr 24 02:09 PM
Schikan Johannes Gerardus Chri	Director	Apr 23 '26	Sale	30.03	100	3,003	388,067	Apr 24 02:09 PM
Lesage Anne	Chief Early Development	Apr 22 '26	Option Exercise	7.69	7,500	57,645	63,450	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 23 '26	Option Exercise	2.59	100	259	56,550	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 22 '26	Sale	30.05	7,500	225,362	56,450	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 22 '26	Sale	30.05	7,000	210,358	156,969	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 23 '26	Sale	30.03	100	3,003	156,869	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 23 '26	Sale	30.03	100	3,003	56,450	Apr 24 12:18 PM
Lu Peng	Chief Medical Officer	Apr 22 '26	Option Exercise	2.59	7,001	18,133	73,084	Apr 24 11:27 AM
Lu Peng	Chief Medical Officer	Apr 23 '26	Option Exercise	2.59	100	259	66,183	Apr 24 11:27 AM
Lu Peng	Chief Medical Officer	Apr 22 '26	Sale	30.05	7,001	210,402	66,083	Apr 24 11:27 AM
Lu Peng	Chief Medical Officer	Apr 23 '26	Sale	30.03	100	3,003	66,083	Apr 24 11:27 AM
GrayMatters Consulting B.V.	Officer	Apr 22 '26	Proposed Sale	29.15	30,000	874,500		Apr 22 05:17 PM
PENG LU	Officer	Apr 22 '26	Proposed Sale	29.15	40,000	1,166,000		Apr 22 04:29 PM
ANNE SIMONNE J. LESAGE	Officer	Apr 22 '26	Proposed Sale	29.15	33,000	961,950		Apr 22 04:29 PM
Hans H. Schikan	Director	Apr 22 '26	Proposed Sale	29.15	40,000	1,166,000		Apr 22 04:28 PM
Modig Berndt	Chief Executive Officer	Apr 16 '26	Sale	28.60	2,292	65,559	139,792	Apr 20 03:00 PM
Berndt B.A.E. Modig	Officer	Apr 16 '26	Proposed Sale	29.14	2,292	66,789		Apr 16 04:15 PM
Modig Berndt	Chief Executive Officer	Apr 09 '26	Sale	27.74	23,333	647,281	142,084	Apr 10 01:42 PM
Berndt B.A.E. Modig	Director	Apr 08 '26	Proposed Sale	27.84	23,333	649,591		Apr 08 04:35 PM
PENG LU	Officer	Jan 02 '26	Proposed Sale	27.75	49,000	1,359,750		Jan 02 04:29 PM
ABELE STEFAN ANDREAS	Officer	Dec 04 '25	Proposed Sale	28.02	4,109	115,120		Dec 04 06:08 PM
JOHANNES GER. CHRIS. PE SCHIKA	Officer	Dec 03 '25	Proposed Sale	24.12	20,000	482,400		Dec 03 04:46 PM
Berndt B.A.E. Modig	Officer	Dec 03 '25	Proposed Sale	24.12	109,583	2,643,142		Dec 03 04:33 PM
PENG LU	Officer	Jul 14 '25	Proposed Sale	25.12	11,307	284,032		Jul 14 04:22 PM
PENG LU	Officer	Jul 11 '25	Proposed Sale	19.83	351	6,960		Jul 11 04:21 PM

PHVS

Pharvaris NV

ADCT

Adc Therapeutics SA

Upgrade your Finviz experience